Which medications are used in the treatment of chronic myelogenous leukemia (CML)?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print

Tyrosine kinase inhibitors for CML

  • Imatinib mesylate (Gleevec): For chronic, accelerated, and blastic phases; standard treatment of choice
  • Dasatinib (Sprycel): For chronic phase
  • Nilotinib (Tasigna): For chronic phase
  • Bosutinib (Bosulif): For chronic, accelerated, and blast phases
  • Ponatinib (Iclusig): For chronic or blast phase  T315I-positive cases, or in appropriate patients in whom no other TKI therapy is tolerated or indicated

Other medications for CML

  • Interferon-alfa: Former first-line agent; now combined with newer drugs for refractory cases
  • Hydroxyurea (Hydrea): Myelosuppressive agent for inducing hematologic remission
  • Busulfan: Myelosuppressive agent for inducing hematologic remission
  • Omacetaxine (Synribo): Protein translation inhibitor indicated for chronic- or accelerated-phase CML with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!